INTERNATIONAL ISOTOPES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0316 USD | -19.87% |
|
-18.51% | -20.75% |
| Sales 2022 | 11.18M 15.3M | Sales 2023 | 12.27M 16.79M | Capitalization | 20.79M 28.45M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 2.01 x |
| Net Debt 2022 | 5.74M 7.85M | Net Debt 2023 | 5.66M 7.74M | EV / Sales 2023 | 2.16 x |
| P/E ratio 2022 |
54.8
x | P/E ratio 2023 |
-23.8
x | Employees | 40 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.59% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -19.87% | ||
| 1 week | -18.51% | ||
| Current month | -16.58% | ||
| 1 month | -18.72% | ||
| 3 months | -20.75% | ||
| 6 months | -36.60% | ||
| Current year | -20.75% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.020.05
1 year
0.020.10
3 years
0.020.15
5 years
0.000.34
10 years
0.000.34
| Managers | Title | Age | Since |
|---|---|---|---|
Shahe Bagerdjian
CEO | Chief Executive Officer | 60 | 23-05-07 |
Matthew Cox
DFI | Director of Finance/CFO | 40 | 19-03-31 |
Steve Laflin
BRD | Director/Board Member | 67 | 01-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | 02-04-23 | |
Steve Laflin
BRD | Director/Board Member | 67 | 01-05-31 |
Robert Atcher
BRD | Director/Board Member | 72 | 17-08-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-25 | 0.0316 | -19.87% | 3,901 |
| 24-06-24 | 0.0395 | +6.04% | 32,000 |
| 24-06-21 | 0.0372 | -4.24% | 63,130 |
| 24-06-20 | 0.0389 | -0.10% | 40,556 |
| 24-06-18 | 0.0389 | -4.09% | 1,000 |
Delayed Quote OTC Markets, June 25, 2024 at 02:08 pm
More quotes
International Isotopes Inc. manufactures a range of radioisotope-focused products. The Companyâs segments include Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products, and Fluorine Products. The Theranostics Products segment includes production and distribution of its generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. The Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications.
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.75% | 16.55M | |
| +1.47% | 30.64B | |
| +26.02% | 8.71B | |
| +11.79% | 8.02B | |
| +20.64% | 5.47B | |
| +13.10% | 3.8B | |
| +4.29% | 3.46B | |
| -18.63% | 3.43B | |
| +9.38% | 3.16B | |
| -10.89% | 2.69B |
- Stock Market
- Equities
- INIS Stock
